Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.

Panicker GK, Karnad DR, Salvi V, Kothari S.

J Assoc Physicians India. 2012 Jan;60:56-61. Review.

PMID:
22715547
2.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.

Oral antidiabetic agents as cardiovascular drugs.

Macfarlane DP, Paterson KR, Fisher M.

Diabetes Obes Metab. 2007 Jan;9(1):23-30. Review.

PMID:
17199715
6.

Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.

Fisman EZ, Tenenbaum A, Motro M, Adler Y.

Herz. 2004 May;29(3):290-8. Review.

PMID:
15167955
8.

[Oral antidiabetic drugs. How to begin and combine without cardiovascular risk].

Duarte R.

Rev Port Cardiol. 2013 Apr;32 Suppl 1:15-24. doi: 10.1016/S0870-2551(13)70043-X. Portuguese.

PMID:
23721975
9.

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.

Cavender MA, Lincoff AM.

Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.

PMID:
20653327
10.

[Glycemic control and cardiovascular benefit: What do we know today?].

Hanefeld M, Schönauer M, Forst T.

Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853. Epub 2010 Feb 9. Review. German.

PMID:
20146161
11.

Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.

Pfützner A, Forst T.

Expert Opin Pharmacother. 2006 Mar;7(4):463-76. Review.

PMID:
16503818
12.

[Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].

Cosmi F, Cosmi D.

G Ital Cardiol (Rome). 2010 Jun;11(6):460-6. Review. Italian.

PMID:
20922871
13.
14.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
15.

Divergent effects of various diabetes drugs on cardiovascular prognosis.

Bell DS, Patil HR, O'Keefe JH.

Rev Cardiovasc Med. 2013;14(2-4):e107-22. Review.

PMID:
24448252
16.

Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?

Papanas N, Maltezos E.

Curr Pharm Des. 2009;15(27):3179-92. Review.

PMID:
19754390
17.

Progress with thiazolidinediones in the management of type 2 diabetes mellitus.

Meriden T.

Clin Ther. 2004 Feb;26(2):177-90. Review.

PMID:
15038941
18.

Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL.

Ann Intern Med. 2007 Sep 18;147(6):386-99. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.

PMID:
17638715
19.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
20.

Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.

Azim S, Baker WL, White WB.

Curr Cardiol Rep. 2014 Nov;16(11):541. doi: 10.1007/s11886-014-0541-0. Review.

PMID:
25303895
Items per page

Supplemental Content

Write to the Help Desk